The Cancer Breakthroughs No One Is Talking About
Inside laboratories across the globe, researchers are quietly waging war against cancer—and scoring remarkable wins.
Take GPNMB, a protein that two independent teams recently discovered hiding on the surface of solid tumors. For years, CAR T cell therapy—where doctors harvest a patient's immune cells, reprogram them to hunt cancer, and infuse them back—worked beautifully on blood cancers but failed spectacularly against solid tumors. The cells simply couldn't find consistent targets.
"Target discovery remains a considerable challenge in the development and translation of CAR T cell therapies for solid tumors," wrote Christopher Mount and Marcela Maus at Massachusetts General Brigham Cancer Institute.
Now, according to Singularity Hub, those two teams have converged on the same promising target: GPNMB. In one study, CAR T cells engineered to recognize GPNMB rapidly destroyed glioblastoma in patient tissues and shrank tumors in mice. A second team used a similar strategy against an aggressive soft tissue cancer—with an early trial participant experiencing disease stabilization for three months without serious side effects.
Reading Cancer's Instruction Manual
Meanwhile, other researchers are rewriting how we understand the disease itself. At Roswell Park Comprehensive Cancer Center, scientists identified a novel metabolic pathway inside the cell nucleus that helps cancer progress by activating genes. When the team shut down this pathway—comprising enzymes that migrate from the cell's "powerhouse" to its nucleus—tumor cells struggled to multiply and spread. "Our work establishes a critical link between metabolism and epigenetic regulation in cancer," said study senior author Subhamoy Dasgupta, Ph.D.
That epigenetic angle appears again in leukemia research. A collaboration between Sweden's Karolinska Institutet and Kyoto University analyzed how genes are regulated without changing DNA itself—the epigenome—in 1,563 patients with acute myeloid leukemia. They identified 16 distinct molecular subgroups, potentially explaining why some patients survive years while others succumb quickly. These findings, published in Nature, could guide more personalized treatment choices.
New Eyes on Old Problems
Sometimes breakthrough comes from looking again at what we've overlooked. When prostate cancer recurs after initial treatment, doctors rely on PSMA PET imaging to locate tumors. But 30% of patients have no detectable disease on first scan, even as rising PSA levels suggest recurrence. New research published in The Journal of Nuclear Medicine found that a second PSMA PET scan changed treatment plans for nearly half of these patients.
"There is little information on the utility of repeating a PSMA PET after an initial negative scan," said Ur Metser, BSc, MD, FRCPC, professor of radiology at the University of Toronto. "In our study, my colleagues and I sought to determine the benefit."
The benefit, it turns out, is substantial.
The Immune System Gets a Boost
Other researchers are finding ways to strengthen the body's own defenses. At Trinity College Dublin and University College Dublin, scientists discovered that a simple yeast dietary supplement helped obese laboratory mice develop stronger cancer-fighting immune cells. Obesity weakens immunity, making tumors harder to combat—but the yeast supplement restored that lost capacity.
"This means yeast-based supplements could become a safe, natural way to help the immune system fight cancer more effectively," said Associate Professor Frederick J. Sheedy, an immunology researcher at Trinity.
In South Korea, a team at Sungkyunkwan University developed a nanoswitch technology that targets tumor-derived extracellular vesicles— nanoscale packages cancer cells release to suppress immune response—while simultaneously boosting the patient's own defenses. The approach, published in Signal Transduction and Targeted Therapy, showed promise against triple-negative breast cancer and colorectal cancer in animal models.
Beyond Cancer
Not all the breakthroughs focus on oncology. Researchers at the University of Gothenburg identified a key protein—glycoprotein G—that allows the genital herpes virus to enter nerve cells, where it establishes lifelong infection. In experiments on mice, understanding this mechanism revealed a potential vaccine target for a disease affecting hundreds of millions worldwide.
Similarly, researchers at VCU Massey Comprehensive Cancer Center, the VCU School of Dentistry, and the University of Pennsylvania discovered previously unrecognized changes in blood vessels that drive rapid progression in oral inflammatory diseases. Their findings, published in Nature Communications, could inform treatments for other inflammatory conditions, including cancer.
What's Next
What unites these disparate discoveries is a deeper understanding of disease at the molecular level—and increasingly, the tools to intervene. Whether it's flipping genetic switches, retraining immune cells, or simply adding a common supplement to one's diet, the gap between laboratory discovery and clinical application is narrowing. For the estimated two million Americans expected to receive a cancer diagnosis this year, these breakthroughs offer something precious: new reasons for hope.
Sign in to join the conversation.
Comments (0)
No comments yet. Be the first to share your thoughts.